Dataset from A Randomized, Open-label, Active-controlled, 3-arm Parallel-group, 26-week Study Comparing the Efficacy and Safety of Lixisenatide to That of Insulin Glulisine Once Daily and Insulin Glulisine Three Times Daily in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine With or Without Metformin

Primary Objective:

- To compare lixisenatide versus insulin glulisine in terms of glycosylated hemoglobin
(HbA1c) reduction and body weight change at Week 26 in type 2 diabetic participants not
adequately controlled on insulin glargine ± metformin.

Secondary Objectives:

- To compare the treatments/regimens on:

- The percentage of participants reaching the target of HbA1c <7% or ≤6.5%,

- Body weight,

- Self-Monitored Glucose profiles,

- Fasting Plasma Glucose (FPG),

- Post-prandial plasma glucose (PPG) /glucose excursions during a standardized meal test
(subset of participants),

- Daily doses of insulins,

- Safety and tolerability.